MIC + L-Carnitine + B12 vs Survodutide
A side-by-side research comparison of MIC + L-Carnitine + B12 and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MIC + L-Carnitine + B12 | Survodutide |
|---|---|---|
| Full name | Lipotropic Injection Blend (Methionine, Inositol, Choline + L-Carnitine + B12) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Compounded medication | Phase 3 Clinical Trial |
| Mechanism | Methionine aids fat breakdown and detoxification. Inositol helps redistribute body fat and improves insulin signaling. Choline prevents fat deposits in the liver. L-Carnitine shuttles fatty acids into mitochondria for oxidation. B12 supports energy metabolism and red blood cell formation. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | Blend (multiple active compounds) | 4,500 Da (approximate) |
| Half-life | Variable by component; B12 ~6 days, L-Carnitine ~17 hours | 5-7 days |
| Bioavailability | ~100% (intramuscular injection) | High (SubQ) |
| Typical dose | 1 mL injection (standardized blend) | 0.6-6.0 mg |
| Frequency | 1-2x weekly | Once weekly |
| Route | Intramuscular injection | Subcutaneous |
MIC + L-Carnitine + B12 reported benefits
- Enhanced fat metabolism
- Increased energy levels
- Liver support and detoxification
- Improved mood and mental clarity
- Support for B12 deficiency
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.